quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:35:48·70d
SECFiling
Vistagen Therapeutics Inc. logo

Vistagen Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

VTGN· Vistagen Therapeutics Inc.
Health Care
Original source

Companies

  • VTGN
    Vistagen Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Dec 17UpdateJefferies$0.90
  • Dec 17UpdateMaxim Group-
  • Dec 17UpdateWilliam Blair-
  • Dec 17UpdateStifel$1.00
  • Dec 7UpdateJefferies$15.00
  • Aug 7UpdateMaxim Group$30.00

Related

  • PR2d
    Vistagen Receives FDA "Study May Proceed" Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
  • SEC10d
    Vistagen Therapeutics Inc. filed SEC Form 8-K: Leadership Update
  • INSIDER14d
    SEC Form 4 filed by Tressler Nick B.
  • INSIDER14d
    SEC Form 4 filed by Singh Shawn
  • INSIDER14d
    SEC Form 4 filed by Prince Joshua S.
  • INSIDER14d
    SEC Form 4 filed by Cote Elissa S.
  • INSIDER14d
    SEC Form 4 filed by Adler Reid G.
  • SEC21d
    Vistagen Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022